Ona Raises $86.6M in Venture Round, One of Spain's Biggest Biotech Fundraises

Why It Matters

The infusion of $86.6 M positions Ona to fast‑track its pipeline, potentially delivering novel therapeutics faster and boosting Spain’s reputation as a biotech hub. It also signals robust capital appetite for AI‑enabled drug discovery in Europe.

Key Takeaways

• Ona secured $86.6 M Series B, led by Seventure Partners.
• Funding will expand Ona’s AI‑driven drug discovery platform across Europe.
• Round includes participation from existing backers and new strategic investors.
• Spain’s biotech sector sees record‑level capital inflow in 2024.
• Ona aims to launch two clinical candidates by 2026.

Pulse Analysis

Ona’s $86.6 million Series B round marks a watershed moment for Spanish biotechnology, illustrating how AI is reshaping drug discovery. By combining machine‑learning algorithms with proprietary biological data, Ona claims to cut target identification timelines dramatically. Investors such as Seventure Partners see the platform as a scalable solution that can de‑risk early‑stage research, a critical need for a continent still catching up with U.S. and Asian biotech spend. The financing not only fuels Ona’s internal R&D but also enables partnerships with larger pharma firms seeking to outsource discovery work.

The capital injection arrives amid a broader surge of venture activity in Europe’s life‑science arena. According to PitchBook, European biotech fundraising hit a record $15 billion in 2024, with Spain contributing an unprecedented share. Ona’s success reflects a maturing ecosystem where local talent, government incentives, and a growing pool of specialized investors converge. For the Spanish economy, high‑growth biotech firms promise high‑value jobs and export potential, reinforcing the country’s strategic shift toward knowledge‑intensive industries.

Looking ahead, Ona plans to advance two pre‑clinical candidates into IND‑enabling studies by 2026, leveraging its AI platform to optimize lead selection and reduce attrition rates. If successful, these programs could attract follow‑on financing or acquisition interest from multinational pharma, further integrating Spain into the global drug development pipeline. The round also sets a benchmark for future Spanish biotech raises, encouraging founders to pursue ambitious, technology‑driven visions backed by substantial capital.

Deal Summary

Spanish biotech company Ona announced a new venture round of $86.6 million, marking one of the largest biotech fundraises in Spain. The round closed on June 6, 2026, providing capital to advance its drug development pipeline.